We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Target for Colon Cancer Treatment

By Biotechdaily staff writers
Posted on 25 Oct 2006
Researchers have discovered a new target for potential uses in future colon cancer treatments--a molecule that is implicated in 85% of colon cancer cases.

The study, performed by researchers from the University of Utah's Huntsman Cancer Institute (Salt Lake City, UT, USA), was published online October 6, 2006, in the Journal of Biological Chemistry. More...
By knocking out (genetically disabling) a molecule called C-terminal binding protein (CTBP), researchers were able to save zebrafish from the effects of a mutation in the adenomatous polyposis coli (APC) gene.

In humans, mutations in this gene have long been known to trigger a series of events that cause colon polyps, which ultimately become cancerous. APC mutations play a role in 85% of colon cancers. The new findings mean CTBP also is involved in that percentage of colon cancers.

In zebrafish, APC mutations keep the intestine from developing correctly. "In essence, knocking out CTPB promotes normal development of the intestine in zebrafish carrying an APC mutation,” stated Dr. David A. Jones, a University of Utah associate professor of oncological sciences and leader of the study.

In normal cells of both humans and zebrafish, the APC gene controls the amount of CTBP present by tagging it for destruction. In tumor cells with mutated APC, CTPB is not destroyed; instead it accumulates in the cell. One function of CTBP is to inactivate the process that converts vitamin A into retinoic acid in the cell. Retinoic acid is essential in cell differentiation--the function that determines what type of cell forms and how long it lives.

This study noted that in both zebrafish and human tissues with APC mutations, there are high CTBP levels and a low capability to produce retinoic acid. In APC-mutated tissues in which CTBP had been knocked out, retinoic acid production was restored. Earlier studies in Dr. Jones' lab demonstrated that the lack of retinoic acid caused zebrafish intestines to form incorrectly, and that adding retinoic acid corrected the problems.

"Knocking out CTBP does exactly the same thing, and the logical conclusion is that it's because CTBP controls retinoic acid production,” remarked Dr. Jones. "Since CTBP is a completely new target, we must now look for potential chemical agents that would work to block its actions. That could take three to five years.”



Related Links:
Huntsman Cancer Institute

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.